Consensus Altimmune, Inc.

Equities

ALT

US02155H2004

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
7.08 ^USD	-6.47%		+0.57%	-37.07%

Apr. 02	Transcript : Altimmune, Inc. - Special Call
Mar. 27	Altimmune Shares Slip Wednesday, After Reporting a Wider Q4 Net Loss and Dropping Prospective Treatment for Hepatitis B	MT

Evolution of the average Target Price on Altimmune, Inc.

Price target over the last 5 years

History of analyst recommendation changes

943894608bf7014e216a4a015.eKt-r8u9qqxhVqv5KxNbjhz_F6yOkX8Ppax5ZIlz1QM.Hucb_4jZ7ssiFJ6aXVs3t227cJjf_0h7wOo_Lb5Ch0RJyUrL-dDE5Qsxkw~9049f6dd3356158f4a6dfb543ac1ceda

Analyst Recommendations on Altimmune, Inc.

B. Riley Raises Altimmune's PT to $20 From $15 on Increased Obesity+NASH Therapeutics' Product Sales Projections; Keeps Buy Rating	Jan. 17	MT
B. Riley Lowers Altimmune's PT to 8 From $15, Says Updated Model Adjusts for Ongoing Obesity+NASH Market Dynamics; Maintains Buy Rating	Nov. 09	MT
HC Wainwright Adjusts Price Target on Altimmune to $15 From $50, Maintains Buy Rating	23-08-14	MT
B. Riley Lowers Altimmune's Price Target to $15 From $20, Keeps Buy Rating	23-08-11	MT
B. Riley Lowers Altimmune's Price Target to $20 From $26, Keeps Buy Rating	23-08-10	MT
Goldman Sachs Downgrades Altimmune to Neutral From Buy, Adjusts Price Target to $6 From $20	23-03-22	MT
HC Wainwright Reiterates Altimmune at Buy With $50 Price Target	23-01-20	MT
Evercore ISI Adjusts Altimmune Price Target to $25 From $14, Maintains Outperform Rating	23-01-18	MT
Goldman Sachs Initiates Altimmune at Buy With $20 Price Target	22-12-01	MT
JMP Securities Adjusts Price Target on Altimmune to $26 From $28, Maintains Market Outperform Rating	22-11-11	MT
Guggenheim Adjusts Altimmune's Price Target to $26 From $31, Reiterates Buy Rating	22-09-16	MT
Jefferies Adjusts Altimmune's Price Target to $35 From $30, Reiterates Buy Rating	22-08-31	MT
HC Wainwright Adjusts Altimmune's Price Target to $50 From $25, Reiterates Buy Rating	22-08-17	MT
B. Riley Securities Raises Altimmune's Price Target to $26 from $21, Increases Likelihood of Technical, Regulatory Success; Keeps Buy Rating	22-08-12	MT
Piper Sandler Adjusts Altimmune's Price Target to $25 From $34, Reiterates Overweight Rating	22-05-18	MT
Guggenheim Adjusts Altimmune's Price Target to $28 From $33, Reiterates Buy Rating	22-03-16	MT
B. Riley Lowers Altimmune's Price Target to $21 from $27 After Revising Cost Capital Assumptions, Keeps Buy Rating	22-01-24	MT
ALTIMMUNE : Piper Sandler Adjusts Altimmune's Price Target to $34 from $16, Keeps Overweight Rating	21-09-08	MT
ALTIMMUNE : B. Riley Raises Altimmune's PT to $27 from $21 Ahead of 12-Week Weight Loss Readout from ALT-801 Study, Keeps Buy Rating	21-09-07	MT
ALTIMMUNE : Jefferies Adjusts Altimmune's Price Target to $30 From $14, Reiterates Buy Rating	21-08-12	MT
ALTIMMUNE : Guggenheim Adjusts Altimmune's Price Target to $42 From $52, Reiterates Buy Rating	21-06-30	MT
ALTIMMUNE : HC Wainwright Adjusts Altimmune's Price Target to $25 From $35, Reiterates Buy Rating	21-06-30	MT
ALTIMMUNE : Piper Sandler Adjusts Altimmune's Price Target to $16 From $80, Reiterates Overweight Rating	21-06-30	MT
ALTIMMUNE : B Riley Lowers Altimmune's PT to $21 from $41 After 'Disappointing' Datasets from AdCOVID Phase 1 Study, Keeps Buy Rating	21-06-30	MT
ALTIMMUNE : JMP Securities Adjusts Altimmune's Price Target to $31 From $53, Maintains Market Outperform Rating	21-06-30	MT